Profile for Sanjay Srivastava, PhD

Sanjay Srivastava

Sanjay Srivastava, PhD

  • Department Chairperson
  • Director
  • University Distinguished Professor
  • Associate Academic Dean
Office Phone: 806-414-9211
Mail Address: 1406 S Coulter St
Amarillo TX 79106-1786


Dr. Sanjay K. Srivastava is currently a Distinguished Professor and Chair of Department of Immunotherapeutics and Biotechnology specializing in Cancer Biology, Chemoprevention and Therapeutics. Previously, he was a Professor in the Department of Biomedical Sciences. Prior to his arrival at TTUHSC, Dr. Srivastava served as an Assistant Professor in the Department of Pharmacology, University of Pittsburgh School of Medicine from 2000-2007 and was a full member of the University of Pittsburgh Cancer Institute. He did his post-doc from the University of Texas Medical Branch at Galveston, Texas from 1992-1995. Dr. Srivastava’s research is focused on melanoma, pancreatic, ovarian and breast cancer and is funded by grants from the National Cancer Institute, NIH. He has authored more than 125 research papers and is the Editor of three books. Dr. Srivastava is in the editorial board of several journals and is the member of societies including American Association for Cancer Research, Society of Toxicology and AAPS. He also serves in the grant review panels of National Institute of Health (NIH), Department of Defense and Susan G. Komen Breast Cancer Foundation. His research work has been featured by news agencies including BBC, MSNBC, CBS, ABC, Science News etc.

Selected Publications:

  • Ranjan A, Srivastava SK. Penfluridol suppresses pancreatic tumor growth by autophagy-mediated apoptosis.. Scientific reports 2016;6:26165.
  • Ranjan A, Gupta P, Srivastava SK. Penfluridol: An Antipsychotic Agent Suppresses Metastatic Tumor Growth in Triple-Negative Breast Cancer by Inhibiting Integrin Signaling Axis.. Cancer research 2016;76(4):877-90.
  • Fofaria NM, Qhattal HS, Liu X, Srivastava SK. Nanoemulsion formulations for anti-cancer agent piplartine-Characterization, toxicological, pharmacokinetics and efficacy studies.. International journal of pharmaceutics 2016;498(1-2):12-22.
  • Fofaria NM, Frederick DT, Sullivan RJ, Flaherty KT, Srivastava SK. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.. Oncotarget 2015;6(38):40535-56.
  • Ranjan A, Fofaria NM, Kim S, Srivastava SK. Modulation of signal transduction pathways by natural compounds in cancer.. Chinese journal of natural medicines 2015;13(10):730-42.